Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2023-11-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于第五届监事会第十五次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a supervisory board meeting of a company regarding stock option incentive plans, including cancellation of some stock options and confirmation of exercise conditions. It includes voting results and compliance statements. The document is short (1193 characters) and does not contain financial statements or detailed financial data. It is a formal announcement of board/management decisions related to stock option plans, which fits best under Board/Management Information (MANG).
2023-11-30 Chinese
关于第五届董事会第十六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of 特一药业集团股份有限公司. It details decisions about stock option incentive plans, including cancellation and exercise conditions. The document includes meeting attendance, voting results, and references to related announcements on a regulatory information website. It does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release. It is not a proxy solicitation or voting results announcement. The content is focused on board decisions and management matters related to stock options. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is a formal announcement of board resolutions, not a report publication or certification. Confidence is high due to clear identification of board meeting and resolutions.
2023-11-30 Chinese
2021年股票期权激励计划第二个行权期可行权激励对象名单
Director's Dealing Classification · 95% confidence The document is a detailed announcement listing the eligible participants for the second exercise period of the 2021 stock option incentive plan of 特一药业集团股份有限公司. It includes specific data on stock options granted, exercisable quantities, and the proportion of total shares, as well as a comprehensive list of core personnel eligible for exercising options. The document is dated December 1, 2023, and is issued by the company's board. This type of document relates to insider share transactions or stock option exercises by company directors and executives. It is not a financial report, earnings release, or general regulatory filing. It fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives, including stock option exercises.
2023-11-30 Chinese
国浩律师（深圳）事务所关于特一药业集团股份有限公司2021年股票期权激励计划注销部分股票期权暨第二个行权期行权条件成就的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of part of a 2021 stock option incentive plan and the achievement of exercise conditions for the second exercise period. It discusses legal compliance, approvals by the board and shareholders, and the fulfillment of conditions for stock option exercises. The document is not a financial report, earnings release, or management discussion but a legal opinion related to stock option plans and their execution. This type of document fits best under Regulatory Filings (RNS) as it is a legal compliance and advisory document related to corporate governance and stock incentive plans, not a direct financial or management report.
2023-11-30 Chinese
独立董事关于相关事项的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent directors' opinion on matters related to the cancellation and exercise conditions of a 2021 stock option incentive plan. It references compliance with relevant laws and company regulations, and confirms the legitimacy and procedural correctness of the stock option plan actions. The document is a formal opinion letter from independent directors rather than a full report or announcement of financial results. It does not contain financial statements or detailed financial data, nor is it a general regulatory filing or announcement of a report publication. It is a specialized governance-related document focused on stock option plan matters, which aligns best with the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Remuneration Information or Share Issue/Capital Change, since it is an independent opinion rather than a direct announcement of share issuance or executive compensation details.
2023-11-30 Chinese
监事会关于2021年股票期权激励计划有关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion regarding the 2021 stock option incentive plan of the company. It discusses the cancellation of some stock options and the fulfillment of exercise conditions for the second exercise period. The content focuses on stock option incentive plan matters, including compliance with laws and regulations, and adjustments to the stock option plan. This is not a full annual or interim report, nor an earnings release or capital update. It is a formal supervisory board opinion on stock option incentive matters, which fits best under Regulatory Filings (RNS) as it is a compliance and regulatory disclosure related to stock options but not a direct capital change announcement or remuneration report. The document length is short and it is a formal opinion, not a report or announcement of a report publication.
2023-11-30 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.